Clinical Trial of PCV13 in Infants Aged Approximately 2 Months (42 to 89 Days)

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2026
A Phase III clinical trial of 13-valent pneumococcal conjugate vaccine (PCV13)developed by Sinovac Life Science Co., Ltd will be conducted in infants aged approximately 2 months (42 to 89 days). The objective of the study is to evaluate the immunogenicity and safety of Sinovac PCV13. The trial is a randomized, double-blind, active controlled phase III clinical trial.
Epistemonikos ID: 5ab021b83e379660c2bf1eb862a3e5df653eceb1
First added on: May 19, 2026